The unconventional CEO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Dietlin, Chief Executive Officer of ELIQUENT Life Science.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• Practical advice on the mindset required when navigating M&A from both sides
• Why he made the move from management consulting into executive search, and why it proved to be the right call
• How the hunter became the hunted when private equity firm GHO Capital came knocking to take him to ELIQUENT
• The challenge of integrating five successful businesses into one unified platform and brand
• Timeless lessons on working with private equity, while balancing senior leadership with family life
• Operating at the forefront of global regulatory change and the evolution of modern drug development

As Chief Executive Officer of ELIQUENT Life Sciences, Tim Dietlin steers the company’s global priorities and strategic growth. His leadership guides ELIQUENT’s team of unmatched regulatory experts and clears the path to better health.

Tim leads ELIQUENT’s global business with a focus on bringing clarity to regulatory complexity. His strategic direction leverages ELIQUENT’s combined capabilities and collective expertise to provide integrated solutions that bridge the spectrum of global regulatory challenges. Under his leadership, ELIQUENT’s platform of comprehensive solutions deliver a full-service engagement that global life sciences innovators need to gain and maintain market authorization for their products.

With more than 25 years of leadership experience, Tim empowers the ELIQUENT team to redefine regulatory excellence and provide continued value to clients. Prior to joining ELIQUENT, Tim served in leadership roles with premier firms advising and serving the life sciences industry, including Campbell Alliance, IBM and Heidrick & Struggles.

Tim holds a BA from Loyola University Chicago, an MBA from DePaul University, and sits on the board of the Chicago chapter of the Juvenile Diabetes Research Foundation (JDRF).

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!